We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 154

Federal Court rejects NIA defence and awards compound interest on patent damages

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 24 2015

On Jan. 23, 2015, the Federal Court released its decision regarding the quantum of damages recoverable by Eli Lilly (“Lilly”) in an action relating

Federal Court determines Minister's decisions granting NOCS based on administrative ANDSs cross-referencing licensed generics without requiring NOAs are wrong

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 10 2015

On December 19, 2014, the Federal Court set aside a decision of the Minister of Health granting a Notice of Compliance (NOC) to Teva authorizing the

Listing patents against combination drugs in Canada ? Changes coming

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • December 1 2014

On Nov. 26, 2014, Industry Canada announced an important proposed change to the eligibility requirements for listing a patent against a drug in

Court of Appeal again interprets utility requirement in Celebrex FCA

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 1 2014

The Federal Court of Appeal has again discussed the so-called “promise doctrine” in its October 30, 2014 decision of Apotex Inc. v. Pfizer Canada Inc

Application for leave to appeal granted - 30 October 2014

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 30 2014

On appeal from the judgment of the Federal Court of Appeal pronounced March 14, 2014. The applicants (collectively, “Sanofi”) are the pat

Dow v NOVA: case summary

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • September 19 2014

In the Federal Court's decision in The Dow Chemical Company et al v NOVA Chemicals Corporation, 2014 FC 844 ("Dow v NOVA"), in the face of a

Experimental testing in patent actions: federal court issues notice to the profession

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • July 16 2014

Experimental testing and patent infringement actions often go hand in hand. With respect to providing notice of experimental testing to other parties

Federal Court of Appeal updates Section 8 damages law

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • July 9 2014

On March 14 2014 the Federal Court of Appeal issued its highly anticipated decisions concerning claims by Teva and Apotex for damages pursuant to

Patentability of computer-implemented inventions: how Canada compares to the United States in view of Alice corp

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, USA
  • -
  • July 7 2014

Every patentee must understand that each patent system has evolved a unique way in which to effectively deal with the limits of patentable subject

Personalized medicine: patent issues in Canada and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union
  • -
  • June 19 2014

"Personalized medicine," in its broadest aspects, is essentially the tailoring of treatments to individual characteristics, needs and preferences